Substitute for form 1449/PTO				Complete if Known		
Sub	stitute for form 1449/P	10		Application Number	09/443,863	
I IN	IFORMATI	ON DISC	CLOSURE	Filing Date	November 19, 1999	
STATEMENT BY APPLICANT				First Named Inventor	Indu Parikh	
١	IAILMEN	I DI AI	. 2.07	Art Unit	1615	
(Use as many sheets as necessary)				Examiner Name	G. S. Kishore	
Sheet	1	of	3	Attorney Docket Number	28069-546001US	

			U.S. PA	TENT DOCUMENTS		
Examiner	Cite No.1	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials*		Number-Kind Code ² (if known)	IMM-DD-1111	Applicant of Cited Document	Figures Appear	
	*	US-3,185,625	05-25-1965	Brown		
	*	US-4,309,404	01-05-1982	DeNeale et al.		
		US-4,440,514	04-03-1984	Keiter et al.		
	*	US-4,452,817	06-05-1984	Glen et al.		
	*	US-4,798,846	01-17-1989			
	*	US-4,800,079	01-24-1989			
	*	US-4,837,028	06-06-1989			
	*	US-5.098,606	03-24-1992			
	*	US-5,154,930	10-13-1992			
	*	US-5,342,625	08-30-1994			
	*	US-5,461,039	10-24-1995	Tschollar et al.		
	*	US-5,760,047	06-02-1998			
	*	US-5.814,324	09-29-1998	Sato et al.		
	*	US-5,891,469	04-06-1999	Amselem		
	*		04-06-1999	Myers		
	*	US-5,919,776	07-06-1999	Hagmann et al.		
	*	US-6,028,054	02-22-2000	Benet et al.		
	*	US-6,121,234	09-19-2000	Benet et al.		
		US-6,180,660	01-30-2001	Whitney et al.		
	*	US-6,193,985	02-27-2001	Sonne		
	*	US-6,248,363	06-19-2001	Patel et al.		
	*	US-6,368,628	04-09-2002	Seth		
	*	US-6,534,088	03-18-2003	Guivarc'h et al.		
	*	US-6,604,698	08-12-2003	Verhoff et al.		
	*	US-6,682,761	01-27-2004			
	*	US-6,696,084	02-24-2004			
	*	US-7,255,877	08-14-2007			
	*	US-20020003179	01-10-2002	Verhoff et al.		
	*	US-20020012675	01-31-2002			
	. *	US-20020012704	01-31-2002			
	*	US-20020013271	01-31-2002			
		US-20020119199	08-29-2002			
		US-20020161032	10-31-2002	Guivarc'h et al.		
		US-20080227763	09-18-2008	Languetin et al.		

Substitute for form 1449/PTO		Complete if Known			
Substitute for form 1445/FTO				Application Number	09/443,863
11	IFORMATIO	N DIS	CLOSURE	Filing Date	November 19, 1999
STATEMENT BY APPLICANT				First Named Inventor	Indu Parikh
OTATEMENT BY ALL EIGHT				Art Unit	1615
(Use as many sheets as necessary)			ecessary)	Examiner Name	G. S. Kishore
Sheet	2	of	3	Attorney Docket Number	28069-546001US

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	т6
	_	FR-2819720-A1	07-26-2002	Fournier Lab Sa		
		GB-2250197-A	06-03-1992	Egyt Gyogyszervegyeszeti Gyar		
		JP-60174726-A	09-09-1985	Nippon Shinyaku Co Ltd English "ABSTRACT" only		
		WO-88/06438-A1	09-07-1988	Liposome Co Inc		L
		WO-96/14830-A1	05-23-1996	Dds Drug Delivery Service Ges et al.		
		WO-98/30360-A1	07-16-1998	Winter Cvd Technik Gmbh et al.		
		WO-98/31360-A1	07-23-1998	Pharma Pass		L
		WO-99/40904-A2	08-19-1999	Merck Patent Gmbh et al.		L
	1	WO-9948477-A1	09-30-1999	Theramex et al.		
		WO-0050007-A1	08-31-2000	Lipocine Inc		_
		WO-00/51572-A1	09-08-2000	Nanosystems et al.		L
		WO-00/76482-A1	12-21-2000	Abbott Lab		L
		WO-01/03693-A1	01-18-2001	Ethypharm Lab Prod Ethiques et al.		L
		WO-0115688-A1	03-08-2001	Banner Pharmacaps Inc		
		WO-0121154-A2	03-29-2001	Rtp Pharma Inc		┸
		WO-02/067901-A1	09-06-2002	Rtp Pharma Inc		
		WO-02/24169-A1	03-28-2002	Rtp Pharma Inc		
		WO-02/24193-A1	03-28-2002	Rtp Pharma Inc		
		WO-02/39983-A2	05-23-2002	Lipocine Inc		
		EP-0330532-A1	08-30-1989	Fournier Innovation Synergie		
	1	EP-0605497-A1	07-13-1994	Medac Klinische Spezialpraep		
	1	WO-01/49262-A1	07-12-2001	Fournier Ind & Sante et al.		

Substitute for form 1449/PTO		Complete if Known			
Suc	salute for form 1449/F10			Application Number	09/443,863
IN	FORMATION	I DI	SCLOSURE	Filing Date	November 19, 1999
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Indu Parikh
OTATEMENT BY 74 TEIGHAN				Art Unit	1615
	(Use as many sheets as necessary)			Examiner Name	G. S. Kishore
Sheet	3	of	3	Attorney Docket Number	28069-546001US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Ellen et al., "Long-term Efficacy and Safety of Fenofibrate and a Statin in the Treatment of Combined Hyperlipidemic", Am. J. Cardiol., 81:60B-65B (1998).	
		"Grant and Hackh's Chemical Dictionary: 5th Edition" McGraw-Hill, Inc. page 212.	
		Guichard et al., Curr. Med. Res.Opin., "A New Formulation of Fenofibrate: Suprabioavailable Tablets", 16(2):134-138 (2000).	
		Lieberman, Herbert and Leon Lachman, Eds., "Tablets", Pharmaceutical Dosage Forms, 1:13 (1980).	
		Luckham, P.F., "The Physical Stability of Suspension Concentrates with Particular Reference to Pharmaceutical and Pesticide Formulations," Pestic. Sci., 25:25-34 (1989).	
		Muller et al., "Nanosuspensions for the I.V. Administration of Poorly Soluble Drugs-Stability During Sterilization and Long-Term Storage," Int'l. Symp. Control. Rel. Bioact. Mat., 22:574- 575 (1995).	
		"Phospholipon® 100H" Technical Data, American Lecithin Co., Oxford, CT.	
		"Phospholipon® 90H" Technical Data, American Lecithin Co., Oxford, CT.	
		"The Molecular Basis of Cell Structure and Function" in Lehninger Biochemistry, Chapter 10	

(1970).		ı
Examiner	Date	
Signatura	Considered	

*EXAMINES: initial if reference considered, whether or not clastion is in conformance with MPEP 809. Draw time through clatton if not in conformance and not considered include copy of the form with next communication to applicant. **CTE No. 1 Those application(s) which are marked with an aingle settins(*) next to the Cite No. are not applied (under 3 CFE 196(1)(2)(iii)) because that application was filled after June 30,000 or is available to the IPW. Application among clastions of undergoing the IPW. Application in united (optional). **See Kinds Codes of USPTO Patient Documents at https://www.next-patients.org/ (and in the patient of the patient of the patient occurrent). It is included on the legal of the figure of the figure of the patient occurrent in the included of the legal of the patient occurrent. It is included on the legal of the figure of the patient occurrent in the included of the legal of the patient occurrent in the included on the occurrent under VIPO Standard S1 (1) if possible. **Applicant is to place a check mark the Eff English patients occurrent.